C. Cohen, E. DeJesus, A. LaMarca, et al., “Similar Virologic and Immunologic Efficacy with Fosamprenavir Boosted with 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial,” HIV Clinical Trials, Vol. 11, No. 5, 2010, pp. 239-247. doi:10.1310/hct1105-239

has been cited by the following article:

• TITLE: Impact of Switch to Fosamprenavir and Addition of Lovaza® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy

  AUTHORS: Franco Felizarta, Anthony Scarsella, Homayoon Khanlou, Winston Young, Lisa Ross, Henry Zhao, Keith Pappa, Belinda Ha

  KEYWORDS: Fish Oil; Fosamprenavir; HIV; Hypertriglyceridemia; Lovaza; Switch; Triglycerides

  JOURNAL NAME: World Journal of AIDS, Vol.2 No.1, March 22, 2012

  ABSTRACT: Background: Managing hypertriglyceridemia in HIV-infected patients often requires multiple pharmacologic strategies. Many protease inhibitors (PIs), one of 6 classes of drugs used to treat HIV, have been associated with hypercholesterolemia and drug interactions. For this study, we examined a dual strategy to manage hypertriglyceridemia in HIV-infected patient taking PIs: 1) switching patients to fosamprenavir (FPV), a PI with fewer drug interactions, and 2) adding prescription fish oil (LOVAZA?), which has been shown to reduce triglycerides. Methods: This multicenter, 24-week study enrolled 36 patients virologically suppressed (HIV-1 RNA